Results from three separate data analyses representing diverse patient populations from real-world clinical practice show that use of the once-daily oral medication INVOKANA (canagliflozin) is associated with significant improvements in blood glucose control (A1C) in adults with type 2 diabetes, even though most patients were already being managed with other blood-glucose-lowering medications, including insulin.
Analyses over a six-month period showed that, among the 4,017 patients who initially used INVOKANA, 80 percent of those patients were receiving treatment with other A1C-lowering medications. Of this subset, approximately 20 percent discontinued one or more of those treatments after starting treatment with the drug.
One of these analyses showed Hispanic and Latino Americans – a group at high risk for developing type 2 diabetes and related complications – had higher baseline A1C levels compared to non-Hispanic and non-Latino Americans, and had average A1C reductions greater than 1 percent with INVOKANA. Findings from a third analysis showed a large proportion of patients achieved A1C and blood pressure goals and a reduction in body weight three months after initiating treatment with the drug and the proportions generally remained stable until the end of the analysis period at 12 months.
The new findings were published in recent issues of Current Medical Research & Opinion and BMC Endocrine Disorders.
“The A1C improvements and goal achievements shown in these analyses with INVOKANA across diverse patients with type 2 diabetes – including those with uncontrolled A1C and from different ethnic groups – are important metrics for providers, payers and reimbursement,” said Wing Chow, PharmD, MPH, Director, Real World Data Analytics & External Partnerships, Johnson & Johnson. “These analyses are consistent with findings from other real-world experience with INVOKANA, which now includes more than 8 million prescriptions to date, and also provide a valuable addition to the large body of evidence from our clinical trial program.”
The retrospective analyses, based on medical and lab data from large administrative claims databases, showed that after initiation of INVOKANA patients with type 2 diabetes who had an average baseline A1C of 8.5 to 8.9 percent achieved an average reduction in A1C of approximately 0.8 percent to 1.1 percent over a 6-month period. One of the analyses showed that patients who had poor glucose control at baseline (A1C greater than 9.0 percent) reduced their A1C level by an average of 1.8 percent after 6 months, with 38 percent of the poorly controlled patients achieving an A1C goal of less than 8 percent.
A1C, or hemoglobin A1C, is used as a measure of average blood glucose over the past two to three months. The American Diabetes Association recommends most adults with type 2 diabetes maintain A1C levels of 7 percent or less. Medicare and many health plans use an A1C level of less than 8 percent as a treatment goal. However, nearly half of all adults with type 2 diabetes do not achieve recommended levels of blood glucose control.
“As a leader in the SGLT2 inhibitor space, we recognize the role we play in helping those with diabetes live healthier lives,” said Paul Burton, MD, PhD, Vice President, Medical Affairs, Janssen. “We are committed to continuously building on our foundation of INVOKANA real world evidence and ensuring this high-quality data is easily accessible so payers can make informed coverage decisions and physicians can make the best treatment choices for their patients”
INVOKANA is used along with diet and exercise to lower blood glucose in adults with type 2 diabetes. It is the number-one prescribed treatment in the newest class of medications called sodium glucose co‐transporter 2 (SGLT2) inhibitors that work with the kidneys to lower A1C. The drug is not indicated for weight loss or as antihypertensive treatment.
Treatment with the drug was generally well tolerated in clinical trials. The most common side effects of include genital yeast infections, urinary tract infection and increase in urination frequency; these side effects led to few discontinuations in clinical trials. – PRNewswire